ONCO Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -2892.23% compared to Onconetix, Inc.'s net margin of --. Onconetix, Inc.'s return on equity of -377.25% beat CEL-SCI Corp.'s return on equity of -266.61%.

Onconetix, Inc. has a consensus price target of --, signalling upside risk potential of 1188250.11%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that Onconetix, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Onconetix, Inc. is more attractive than CEL-SCI Corp..

Onconetix, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Onconetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onconetix, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Onconetix, Inc. quarterly revenues are $303.7K, which are larger than CEL-SCI Corp. quarterly revenues of --. Onconetix, Inc.'s net income of -$8.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Onconetix, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onconetix, Inc. is 1.22x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -2892.23% compared to Onconetix, Inc.'s net margin of --. Onconetix, Inc.'s return on equity of -377.25% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Onconetix, Inc. has a consensus price target of --, signalling upside risk potential of 1188250.11%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1212.77%. Given that Onconetix, Inc. has higher upside potential than GT Biopharma, Inc., analysts believe Onconetix, Inc. is more attractive than GT Biopharma, Inc..

Onconetix, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Onconetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onconetix, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Onconetix, Inc. quarterly revenues are $303.7K, which are larger than GT Biopharma, Inc. quarterly revenues of --. Onconetix, Inc.'s net income of -$8.8M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Onconetix, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onconetix, Inc. is 1.22x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veru, Inc. has a net margin of -2892.23% compared to Onconetix, Inc.'s net margin of -128.15%. Onconetix, Inc.'s return on equity of -377.25% beat Veru, Inc.'s return on equity of -95.96%.

Onconetix, Inc. has a consensus price target of --, signalling upside risk potential of 1188250.11%. On the other hand Veru, Inc. has an analysts' consensus of $19.75 which suggests that it could grow by 693.17%. Given that Onconetix, Inc. has higher upside potential than Veru, Inc., analysts believe Onconetix, Inc. is more attractive than Veru, Inc..

Onconetix, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Veru, Inc. has a beta of -1.007, suggesting its less volatile than the S&P 500 by 200.726%.

Onconetix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veru, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onconetix, Inc. pays -- of its earnings as a dividend. Veru, Inc. pays out -- of its earnings as a dividend.

Onconetix, Inc. quarterly revenues are $303.7K, which are larger than Veru, Inc. quarterly revenues of --. Onconetix, Inc.'s net income of -$8.8M is lower than Veru, Inc.'s net income of -$7.3M. Notably, Onconetix, Inc.'s price-to-earnings ratio is -- while Veru, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onconetix, Inc. is 1.22x versus 42.44x for Veru, Inc.. Usually stocks with elevated PS ratios are considered overvalued.